Beta‐cell function in treatment‐naïve patients with type 2 diabetes mellitus: Analyses of baseline data from 15 clinical trials-Reference-Cited by-同舟云学术

Beta‐cell function in treatment‐naïve patients with type 2 diabetes mellitus: Analyses of baseline data from 15 clinical trials

Published:2023-01-11 Issue:5 Volume:25 Page:1403-1407
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obesity Metabolism

Author:

Blüher Matthias¹²^ORCID,Malhotra Ankur³,Bader Giovanni⁴

Affiliation:

1. Medical Department III – Endocrinology, Nephrology, Rheumatology University of Leipzig Medical Center Leipzig Germany

2. Helmholtz Institute for Metabolic, Obesity and Vascular Research (HI‐MAG) of the Helmholtz Zentrum München University of Leipzig and University Hospital Leipzig Leipzig Germany

3. Novartis Healthcare Private Limited Mumbai India

4. Novartis Pharma AG Basel Switzerland

Funder

Novartis

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.14969

Reference22 articles.

1. β-cell dysfunction: Its critical role in prevention and management of type 2 diabetes

2. U.K. Prospective Diabetes Study 16: Overview of 6 Years' Therapy of Type II Diabetes: A Progressive Disease

3. The duration of diabetes affects the response to intensive glucose control in type 2 subjects: the VA Diabetes Trial

4. The Early Treatment of Type 2 Diabetes

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Baseline phenotypes with preserved β-cell function and high insulin concentrations have the best improvements in glucose tolerance after weight loss: results from the prospective DEXLIFE and EGIR-RISC studies;Metabolism;2024-06

2. Improvement of β-Cell Function After Switching From DPP-4 Inhibitors to Oral Semaglutide: SWITCH-SEMA2 Post Hoc Analysis;The Journal of Clinical Endocrinology & Metabolism;2024-05-02

3. Expert Opinion on Current Trends in the Use of Insulin in the Management of People with Type 2 Diabetes from the South-Eastern European Region and Israel;Diabetes Therapy;2024-03-12

4. Favorable Effect of Pemafibrate on Insulin Resistance and β-Cell Function in Subjects with Type 2 Diabetes and Hypertriglyceridemia: A Subanalysis of the PARM-T2D Study;Pharmaceutics;2023-06-27